Position in AKTS
as of Mar 31, 2026
· filed May 28, 2026
Position Value
$8,382,645
New position
Shares Held
468,566
first reported quarter
Ownership
0.848%
of shares outstanding
% of Portfolio
1.43%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Avidity Partners Management LP holds $473,301,645 across 29 Biotechnology names. AKTS ranks #10 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
2,104,184 | $176,583,121 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,288,948 | $87,236,000 | |
| 3 | IMUX |
Immunic, Inc.
|
6,699,411 | $74,363,462 | |
| 4 | ORKA |
Oruka Therapeutics, Inc.
|
760,424 | $37,298,797 | |
| 5 | JBIO |
Jade Biosciences, Inc.
|
1,400,708 | $19,679,947 | |
| 6 | ELVN |
Enliven Therapeutics, Inc.
|
400,000 | $15,680,000 | |
| 7 | CNTX |
Context Therapeutics Inc.
|
4,998,267 | $13,095,459 | |
| 8 | PVLA |
Palvella Therapeutics, Inc.
|
70,000 | $8,725,500 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,382,645 | 468,566 | Shares | Sole | 2026-05-28 | |
| No filing history on record for this holder in this stock. | ||||||